Instead, hs-cTn should continue to be interpreted strictly as a marker of myocardial necrosis, while infection risk assessment should rely on inflammatory biomarkers (e.g., CRP and leukocyte count) and standardized surveillance criteria, integrated with clinical and procedural risk factors. The gene discussed is CRP; the disease is infection.